In recent years, immunotherapy has rapidly risen in the field of cancer treatment, representing a groundbreaking advancement in modern medicine. This approach harnesses the body’s own immune system to identify and attack tumor cells, offering a more precise and personalized treatment compared to traditional chemotherapy or targeted therapies. However, many tumors evade immune attacks through mechanisms such as altering their metabolic microenvironment, weakening the clinical efficacy of immunotherapy. This finding has spurred the development of immunometabolism, presenting new opportunities for next-generation immunotherapies.
Immunometabolism is an emerging field combining immunology and metabolism, which has become a global focus in the medical industry. It primarily explores how metabolic pathways in immune cells regulate the immune system, particularly in anti-tumor responses. Pilatus Biosciences, led by CEO and co-founder Yun-Han Lin, focuses on understanding how tumor cells manipulate the tumor microenvironment by depleting essential nutrients and producing harmful metabolic waste, which impairs immune cell activation. Immunometabolism helps to reveal how these metabolic changes affect the function of T cells and other immune cells, paving the way for therapies that modulate the tumor's metabolic environment and enhance the effectiveness of immunotherapy.
Pilatus Biosciences is committed to developing innovative immunometabolic therapies and has initiated preclinical and translational medical research studies at renowned global institutions and medical centers. The company has also built several research and development pipelines around immunometabolism.
Promising Results from the New Antibody Drug PLT012 in Animal Models
Pilatus Biosciences was co-founded by Ping-Chih Ho, a professor at the University of Lausanne, and Yun-Han Lin, Ph.D., with a focus on developing first-in-class antibody drugs targeting metabolic checkpoints. Through cutting-edge biotechnology, Pilatus aims to provide novel solutions for cancer treatment, overcoming the limitations of existing therapies. The research team boasts extensive expertise in immunology, oncology, and biotechnology, providing a solid foundation for innovative drug development. Their goal is to continuously advance the field of cancer treatment and offer more effective and safer therapeutic options to meet medical needs.
Pilatus' first antibody drug, PLT012, holds groundbreaking therapeutic potential. By modifying metabolic pathways, PLT012 regulates the tumor immune microenvironment, aiding the healthcare industry in the fight against cancer. Specifically, PLT012 blocks CD36 to inhibit fatty acid uptake, reprogramming the metabolic pathways of immune cells within the tumor microenvironment. This enhances the tumor-killing effect of immune cells, effectively suppressing tumor growth and metastasis. PLT012 has already shown promising results in animal models of liver and colorectal cancers. These findings have been presented at multiple international cancer conferences and recognized by pharmaceutical organizations worldwide for collaborative efforts.
Ping-Chih Ho, co-founder of Pilatus and a leading scientist in immunometabolism, has been instrumental in the company’s success. His research focuses on how immune cells regulate their response to the tumor environment through metabolic pathways. His in-depth studies of T-cell metabolism within the tumor microenvironment have laid a strong scientific foundation for the development of novel immunotherapies and are a key factor in Pilatus' impressive achievements.
Expanding Operations in Taiwan to Enhance R&D and Fundraising Capabilities
Pilatus has a solid research foundation and advanced analytical techniques in immunometabolism. To accelerate drug development, the company has partnered with renowned European cancer centers to establish an ex-vivo patient sample culture platform. This platform retains the tumor microenvironment and related cell populations from patient samples, allowing for drug efficacy evaluation across multiple cancers. Pilatus plans to establish a laboratory in Taiwan by July 2024 to expand its research capabilities. This technology not only provides more accurate diagnostic data for personalized medicine but also assists in selecting clinical trial indications and developing biomarkers for new drug development, significantly reducing potential risks in the process and advancing personalized medicine.
Yun-Han Lin, CEO of Pilatus, noted that Taiwan’s pharmaceutical research, preclinical, and clinical trial services have matured in recent years, positioning the country as a global leader. To accelerate the company's growth, Pilatus has partnered with Mosaic Venture Labs Accelerator since 2023, leveraging its influence and resources in the Asia-Pacific region to drive Pilatus’ growth in Taiwan through various research and development stages. The company has also formed partnerships with several Taiwanese research institutions, and plans to establish a strong, flexible operations team in Taiwan. Pilatus expects to begin Phase I clinical trials of PLT012 in Taiwan and the U.S. by early 2025. Meanwhile, Mosaic Venture Labs is assisting the company in raising millions of dollars in a new round of funding, drawing on its biotech venture network in Taiwan to lay the groundwork for Pilatus’ future development. The company is optimistic that its breakthroughs in drug development will provide more treatment options and opportunities for patients.
Resource (mandarin): 佩圖思免疫療法重大突破 抗腫瘤效果令人驚豔
